Only months after Healthtronics withdrew its offer to acquire Endocare for $2.28 per share, Endocare and privately held Galil Medical have agreed to merge. The combined company will be focused on the development of cryoablation technologies, a minimally invasive method to freeze and destroy cancerous tumors. “This combination has the potential to eliminate millions of dollars in redundant costs and we believe that annualized cost savings of over $10 million could be realized by mid-2010. We expect that this transaction will result in positive adjusted EBITDA within 18 months after the close of the transaction,” said Michael Rodriguez, Endocare’s CFO.…
Browsing: Uncategorized
Third quarter revenues at Clarient increased 59% to $19.0 million from the $11.9 million reported in Q3 2007. This marks the company’s 17th consecutive quarter of sequential revenue growth. Higher testing volume, a favorable service mix and higher Medicare reimbursement rates drove revenues. Testing volume for the third quarter of 2008 increased 53% year-over-year. The company will add several new growth drivers in coming months. These include the launch of the long awaited Insight Dx Breast Cancer Profile, and the introduction of the Insight Dx Prostate Profile, licensed from Health Discovery Corporation. In September, Clarient announced that, with Definiens, it…
Meet the most important people in medical technology at In3 East, the largest East Coast strategic partnership and investment meeting for senior-level medical technology executives. Hundreds of venture capital companies and medical technology companies will gather to learn about the latest innovations and investment opportunities. Beyond providing an opportunity for companies to gain exposure to the venture community, it is a convenient ‘watering hole’ for medtech executives to find and build new relationships to support their efforts. The companies that are selected to present at Medtech Insight’s conferences offer investors a meaningful opportunity to conduct effective due diligence during a…
In a move that could accelerate the growth of the Clarient’s biomarker business, the company announced Friday that, with Definiens, it will develop and commercialize tools to help evaluate quantitative biomarkers that predict cancer treatment response. Definiens’ platform uses image analysis algorithms to analyze multi-dimensional image data, regardless of file type, complexity or size. The software can be used to automatically identify and quantify regions of interest within breast, prostate and colon cancer tissue samples. Clarient processes large numbers of tissue samples for both clinical decision-making and drug development. These tissue samples are converted into high-resolution digital images that are…
San Diego Sexual Medicine at Alvarado Hospital, led by physician Irwin Goldstein, attempts to improve sexual health through the prevention, diagnosis, treatment, and rehabilitation of conditions or diseases that involve sexual function. Current areas of research and exploration include: Bicycle Riding: Cardiovascular exercise such as jogging, racket ball, running, swimming and tennis has been associated with decreased prevalence of erectile dysfunction. While bicycle riding is a form of cardiovascular exercise, bicycle riding is associated with an increased prevalence of erectile dysfunction. Diabetes: Diabetes mellitus and metabolic syndrome are common health problems in our society. Men who have these conditions often…
Back in 2004, shares of Rita Medical surged as much as 67 percent after it reported positive results for its radio-frequency ablation (RFA) technology in a trial of lung cancer patients. The RFA system, which uses radio-frequency energy to heat tissue to a high enough temperature to kill cells, achieved a 91 percent survival rate in a trial of patients with primary nonsmall-cell lung cancer after both 12 months and 18 months. AngioDynamics, having acquired Rita in early 2007, continues to pursue expanded indications for Rita’s RFA tools. RFA is currently an option for inoperable tumors. The Rapture study was…
Aureon Laboratories is developing predictive and personalized cancer treatment options. Aureon employs a unique ‘systems pathology’ approach to provide personalized test results by analyzing a patient’s existing biopsy sample using molecular diagnostics, tissue-based image analysis and mathematics. Prostate Px, Aureon’s principal product, provides objective analysis of the patient’s biopsy tissue, enabling more-informed, actionable decisions prior to prostate cancer treatment.
Colon cancer is among the most preventable cancers when caught early. More than 82 million Americans are eligible for colorectal cancer screening. Currently, diagnostics are underutilized due in part to the invasive nature of screening procedures. The most common diagnostic procedures is the oft-dreaded colonoscopy. It’s recommended that individuals 50 and up get one – some 90% of colon cancers occur in this age group. During the exam, a colonoscope, a long, slender, flexible tube attached to a video camera is used to view the colon and rectum. Polyps found during the procedure are typically biospied and analyzed. A less-invasive…